Oct 27 (Reuters) - The European Medicines Agency (EMA) on Friday said available evidence does not support a causal association between GLP-1 receptor agonist drugs, which include Novo Nordisk's weight loss treatment Wegovy, and thyroid cancer. (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Varun H K)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
917.1 DKK | +0.78% | +3.84% | +31.37% |
15/05 | Health Care Up on Momentum -- Health Care Roundup | DJ |
15/05 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.37% | 59TCr | |
-2.60% | 36TCr | |
+20.83% | 33TCr | |
+5.69% | 29TCr | |
+14.83% | 24TCr | |
+9.93% | 21TCr | |
-6.95% | 20TCr | |
+10.77% | 17TCr | |
+0.10% | 16TCr | |
+0.89% | 12TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- EU regulator says no direct link between GLP-1 drugs and thyroid cancer